Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation

키워드

참고문헌 (84)

1. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
2. Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
3. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
4. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
5. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
6. January CT, "2019 AHA", ACC, ACC, pp.HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology, American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[DOI]
7. Eriksson BI, "Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial", Lancet, 370, pp.949~956 (2007)
8. Eriksson BI, "Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial", J Thromb Haemost, 5, pp.2178~2185 (2007)
9. Eriksson BI, "Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty", N Engl J Med, 358, pp.2765~2775 (2008)
10. Kakkar AK, "Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial", Lancet, 372, pp.31~39 (2008)
11. Lassen MR, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty", N Engl J Med, 358, pp.2776~2786 (2008)
12. Hart RG, "Embolic strokes of undetermined source: the case for a new clinical construct", Lancet Neurol, 13, pp.429~438 (2014)
13. Hart RG, "Rivaroxaban for stroke prevention after embolic stroke of undetermined source", N Engl J Med, 378, pp.2191~2201 (2018)
14. Diener HC, "Dabigatran for prevention of stroke after embolic stroke of undetermined source", N Engl J Med, 380, pp.1906~1917 (2019)
15. Kamel H, "The AtRial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods", Int J Stroke, 14, pp.207~214 (2019)
16. Geisler T, "Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design", Int J Stroke, 12, pp.985~990 (2017)
17. Ntaios G, "Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis", Stroke, 50, pp.2477~2485 (2019)
18. Mas JL, "Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke", N Engl J Med, 377, pp.1011~1021 (2017)
19. Kasner SE, "Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial", Lancet Neurol, 17, pp.1053~1060 (2018)
20. Saposnik G, "Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association", American Stroke Association, 2011, pp.42, 1158~1192
21. Geisbüsch C, "Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients", Stroke, 45, pp.2469~2471 (2014)
22. Mendonça MD, "Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients", Int J Stroke, 10, pp.1115~1118 (2015)
23. Rao SK, "Apixaban for the treatment of cerebral venous thrombosis: a case series", J Neurol Sci, 381, pp.318~320 (2017)
24. Mohammad Wasay, "New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study", 대한뇌졸중영문학회지, 21(2), pp.220~223 (2019), 대한뇌졸중학회[DOI]
25. Ferro JM, "European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis: endorsed by the European Academy of Neurology", Eur Stroke J, 2, pp.195~221 (2017)
26. Ferro JM, "Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis", Int J Stroke, 13, pp.766~770 (2018)
27. Kate M, "Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation", Stroke, 46, pp.2685~2687 (2015)
28. Ng KH, "Dabigatran following acute transient ischemic attack and minor stroke II (DATAS II)", Int J Stroke, 12, pp.910~914 (2017)
29. Ibanez B, "2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC)", Eur Heart J, 39, pp.119~177 (2018)
30. Amsterdam EA, "2014 AHA", ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology, Circulation, pp.2014, 130[DOI]
31. Réganon E, "Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction", Haematologica, 87, pp.740~745 (2002)
32. Ardissino D, "Coagulation activation and long-term outcome in acute coronary syndromes", Blood, 102, pp.2731~2735 (2003)
33. Christersson C, "Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction", J Thromb Haemost, 3, pp.2245~2253 (2005)
34. Oldgren J, "Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial", Eur Heart J, 32, pp.2781~2789 (2011)
35. Mega JL, "Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial", Lancet, 374, pp.29~38 (2009)
36. Mega JL, "Rivaroxaban in patients with a recent acute coronary syndrome", N Engl J Med, 366, pp.9~19 (2012)
37. APPRAISE Steering Committee, "Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial", Circulation, 119, pp.2877~2885 (2009)
38. Alexander JH, "Apixaban with antiplatelet therapy after acute coronary syndrome", N Engl J Med, 365, pp.699~708 (2011)
39. Ohman EM, "Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial", Lancet, 389, pp.1799~1808 (2017)
40. Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease", N Engl J Med, 377, pp.1319~1330 (2017)
41. Anand SS, "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial", Lancet, 391, pp.219~229 (2018)
42. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
43. Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
44. Lopes RD, "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation", N Engl J Med, 380, pp.1509~1524 (2019)
45. Lip GYH, "2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), 2019, pp.21, 192~193
46. Vranckx P, "Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial", Am Heart J, 196, pp.105~112 (2018)
47. Lee M, "Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis", Circ Heart Fail, 6, pp.287~292 (2013)
48. Zannad F, "Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease", N Engl J Med, 379, pp.1332~1342 (2018)
49. Greenberg B, "Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDERHF Trial", JAMA Cardiol, 4, pp.515~523 (2019)
50. Falck-Ytter Y, "Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2Suppl), pp.e278~e325 (2012)
51. RE-MOBILIZE Writing Committee, "Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery", J Arthroplasty, 24, pp.1~9 (2009)
52. Eriksson BI, "Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATEII*): a randomised, double-blind, non-inferiority trial", Thromb Haemost, 105, pp.721~729 (2011)
53. Friedman RJ, "Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials", Thromb Res, 126, pp.175~182 (2010)
54. Turpie AG, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial", Lancet, 373, pp.1673~1680 (2009)
55. Turpie AG, "Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies", Thromb Haemost, 105, pp.444~453 (2011)
56. Lassen MR, "Apixaban or enoxaparin for thromboprophylaxis after knee replacement", N Engl J Med, 361, pp.594~604 (2009)
57. Lassen MR, "Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial", Lancet, 375, pp.807~815 (2010)
58. Lassen MR, "Apixaban versus enoxaparin for thromboprophylaxis after hip replacement", N Engl J Med, 363, pp.2487~2498 (2010)
59. Fuji T, "Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial", Thromb Res, 134, pp.1198~1204 (2014)
60. Fuji T, "Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V", Thromb J, 13, pp.27~ (2015)
61. Kawai Y, "Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials", Thromb J, 14, pp.48~ (2016)
62. Schulman S, "Dabigatran versus warfarin in the treatment of acute venous thromboembolism", N Engl J Med, 361, pp.2342~2352 (2009)
63. Schulman S, "Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis", Circulation, 129, pp.764~772 (2014)
64. Schulman S, "Extended use of dabigatran, warfarin, or placebo in venous thromboembolism", N Engl J Med, 368, pp.709~718 (2013)
65. EINSTEIN Investigators, "Oral rivaroxaban for symptomatic venous thromboembolism", N Engl J Med, 363, pp.2499~2510 (2010)
66. EINSTEIN–PE Investigators, "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism", N Engl J Med, 366, pp.1287~1297 (2012)
67. Agnelli G, "Oral apixaban for the treatment of acute venous thromboembolism", N Engl J Med, 369, pp.799~808 (2013)
68. Agnelli G, "Apixaban for extended treatment of venous thromboembolism", N Engl J Med, 368, pp.699~708 (2013)
69. Hokusai-VTE Investigators, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism", N Engl J Med, 369, pp.1406~1415 (2013)
70. Kearon C, "Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report", Chest, 149, pp.315~352 (2016)
71. Mazzolai L, "Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function", Eur Heart J, 39, pp.4208~4218 (2018)
72. Blom JW, "Malignancies, prothrombotic mutations, and the risk of venous thrombosis", JAMA, 293, pp.715~722 (2005)
73. Raskob GE, "Edoxaban for the treatment of cancer-associated venous thromboembolism", N Engl J Med, 378, pp.615~624 (2018)
74. Young AM, "Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)", J Clin Oncol, 36, pp.2017~2023 (2018)
75. McBane Ii R, "Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial", Thromb Haemost, 117, pp.1952~1961 (2017)
76. McBane RD, "Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial", Blood, 132(Suppl 1), pp.421~ (2018)
78. Kahn SR, "Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2 Suppl), pp.e195S~e226S (2012)
79. Hull RD, "Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial", Ann Intern Med, 153, pp.8~18 (2010)
80. Cohen AT, "Rivaroxaban for thromboprophylaxis in acutely ill medical patients", N Engl J Med, 368, pp.513~523 (2013)
81. Goldhaber SZ, "Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients", N Engl J Med, 365, pp.2167~2177 (2011)
82. Cohen AT, "Extended thromboprophylaxis with betrixaban in acutely ill medical patients", N Engl J Med, 375, pp.534~544 (2016)
83. Gibson CM, "Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban)", Circulation, 135, pp.648~655 (2017)
84. Pengo V, "Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome", Blood, 132, pp.1365~1371 (2018)

관련 논문AI추천